Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.

PloS one - 1 Jan 2020

Banda Malathi, McKim Karen L, Myers Meagan B, Inoue Masahiro, Parsons Barbara L

Abstract excerpt

A model that recapitulates development of acquired therapeutic resistance is needed to improve oncology drug development and patient outcomes. To achieve this end, we established methods for the preparation and growth of spheroids from primary human lung adenocarcinomas, including methods to culture, passage, monitor growth, and evaluate changes in mutational profile over time. Primary lung tumor spheroids were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Organoids

Share to Spheroids, Cellular

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 32898185
DOI: 10.1371/journal.pone.0238862
PMCID: PMC7478813

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.PMID 32898185Read ↗

Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.Semantic proximity Read ↗

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapySemantic proximity Read ↗

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerSemantic proximity Read ↗

EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.Semantic proximity Read ↗

Microfluidic Platform for Drug Response Profiling in NSCLC Patient-Derived OrganoidsSemantic proximity Read ↗

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.Semantic proximity Read ↗

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.Semantic proximity Read ↗

Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP SignalingSemantic proximity Read ↗

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.Semantic proximity Read ↗

Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.Semantic proximity Read ↗

Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies.Semantic proximity Read ↗

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.